Related Experiment Video

Updated: Jul 7, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth

M Mann1, H Sheng, J Shao

  • 1Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37232-2279, USA.

Gastroenterology
|May 29, 2001
PubMed
Abstract

Insights

Targeting both cyclooxygenase 2 (COX-2) and ErbB/HER pathways with inhibitors like celecoxib and Herceptin shows promise. Combined treatment effectively inhibits colorectal carcinoma growth, offering a novel therapeutic strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Cyclooxygenase 2 (COX-2) and ErbB/HER pathways are key regulators of cancer cell proliferation.
  • Colorectal carcinoma growth is influenced by these signaling pathways.

Purpose of the Study:

  • To investigate the effects of a COX-2 inhibitor and an anti-HER-2/neu antibody on colorectal carcinoma cell growth.
  • To evaluate the efficacy of combination therapy targeting both pathways.

Main Methods:

  • Cell proliferation assays were used to assess HCA-7 cell response to heregulin beta-1 (HRGbeta-1).
  • In vitro and in vivo studies evaluated the impact of celecoxib (COX-2 inhibitor) and anti-HER-2/neu antibodies (Herceptin, 2C4) on tumor growth.

Main Results:

  • HCA-7 cells express HER-2/neu, and HRGbeta-1 significantly stimulates their growth.
  • Celecoxib and Herceptin individually inhibited HCA-7 cell growth in vitro and in vivo.
  • Combination therapy demonstrated additive effects, leading to near-complete inhibition of tumor growth.

Conclusions:

  • Combined inhibition of COX-2 and HER-2/neu pathways is more effective in reducing colorectal carcinoma growth than monotherapy.
  • Targeting both COX-2 and ErbB signaling pathways presents a novel therapeutic approach for colorectal cancer treatment and prevention.

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...